At least 15% of patients with asthma have a poor response to standard therapy with inhaled glucocorticoids and long-acting bronchodilators.¹ Even after nonadherence to treatment and inadequate inhalation technique are addressed, a substantial percentage of patients continue to have frequent exacerbations and hospitalizations.² Over the past three decades, research has led to an improved understanding of the complex biologic mechanisms of airway inflammation. This, in turn, has led to the development of several monoclonal antibody–based, targeted add-on treatments for asthma that are approved by the Food and Drug Administration or are in phase 3 of development. These include monoclonal antibodies . . .

中文翻译：

---

向上游迁移—持续性不受控制的哮喘中的抗TSLP

至少有15％的哮喘患者对吸入糖皮质激素和长效支气管扩张剂的标准疗法反应较差。¹即使解决了不坚持治疗和吸入技术不足的情况，仍有相当一部分患者继续加重病情和住院治疗。²在过去的三十年中，研究导致人们对气道炎症的复杂生物学机制有了更深入的了解。反过来，这又导致了几种基于单克隆抗体的针对性哮喘的附加疗法的开发，这些疗法已获得美国食品药品监督管理局的批准或处于开发的第三阶段。这些包括单克隆抗体。。。